Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 12,657 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period A Clear all

Conditions: SLC6A1
Interventions: Glycerol Phenylbutyrate; Drug
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 2 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: San Diego, California

Conditions: Chronic Lymphocytic Leukemia
Interventions: Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • Stanford, California + 10 more

Conditions: Migraine
Interventions: DC Stimulator (Transcranial Direct Current Stimulator); Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Exercise, Isometric
Interventions: Isometric exercises, No exercise; Other
Lead sponsor: Carrick Institute for Graduate Studies; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Cape Canaveral, Florida

Conditions: Lymphoma
Interventions: filgrastim, recombinant interferon alfa, Etoposide, cyclophosphamide, doxorubicin hydrochloride, lamivudine, prednisone, vincristine sulfate, zidovudine; Biological · Drug
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years to 120 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 3
States / cities: Los Angeles, California • Miami, Florida • St Louis, Missouri

Conditions: Acute Leukemia
Interventions: Lenalidomide; Drug
Lead sponsor: Mehrdad Abedi, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Health Behavior
Interventions: Sequential MBC Condition, Simultaneous MBC Condition, Stress Management; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Emotional Regulation, Adolescent Behavior
Interventions: DEEP VR; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 13 Years to 17 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chronic Kidney Disease
Interventions: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 44
States / cities: Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more

Conditions: Healthy
Interventions: JNJ-42165279, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Cypress, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Artificial Pancreas App; Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Heparin-induced Thrombocytopenia
Interventions: VLX-1005, Argatroban; Drug
Lead sponsor: Veralox Therapeutics; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Substance Abuse
Interventions: Brief Strategic Family Therapy (BSFT), Treatment as Usual; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 12 Years to 17 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 7
States / cities: Tucson, Arizona • Tarzana, California • Thornton, Colorado + 4 more

Conditions: Scleroderma
Interventions: Brain Boost group, Waitlist group; Behavioral · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cancer
Interventions: Telemedicine Pain Management Intervention (immediate group), Telemedicine Pain Management Intervention (waitlist group, intervention administered following 4-week waitlist period); Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 12 Years to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Adult Participants
Interventions: Oral [14C] PF-07248144, Oral unlabeled PF-07248144, IV [14C] PF-07248144; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Overweight, Obesity
Interventions: Family Program for the Prevention of Weight Gain, Control Group; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 3 Years to 65 Years
Enrollment: 418 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Liver Cirrhosis
Interventions: Zibotentan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Interventions: Inebilizumab, Placebo; Drug · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more

Conditions: Type 1 Diabetes
Interventions: FCL+BPS, FCL; Device
Lead sponsor: Marc Breton; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hot Flashes
Interventions: fezolinetant, placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 1,831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 142
States / cities: Andalusia, Alabama • Birmingham, Alabama • Ensley, Alabama + 108 more

Conditions: Pancreatic Cancer
Interventions: Resistance Training (RT) and Protein Supplementation (PS), Resistance Training (RT), Attention Control (AC; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Standard of Care, P2P Intervention
Interventions: P2P Intervention; Behavioral
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
Interventions: RO7204239, RO7204239 Matching Placebo, Tirzepatide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Anniston, Alabama • Spring Valley, California • Clermont, Florida + 16 more

Search by objective public record fields.

A Fully Remote Feasibility Trial of Phenylbutyrate for SLC6A1-Related Disorders

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Migraine--Investigational Treatment of Migraine With Noninvasive Brain Stimulation. (tDCS- Migraine)

Effects of Isometric Exercises on Balance, Heart Rate, Pulse Ox and Blood Pressure

Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma

Phase I Study of Lenalidomide in Patients With Acute Leukemia

Make Better Choices

Virtual-reality and Emotion Regulation in Violence-Exposed Youth

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants

Safety and Feasibility Evaluation of the APS APP

A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

Brief Strategic Family Therapy for Adolescent Drug Abusers

Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis

Adolescent Cancer Telemedicine for Pain Management

A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy Adults

Family Program for Weight Gain Prevention

A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants

N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Evaluation of The Postprandial Impact of Automated Priming Bolus for Full Closed Loop Insulin Delivery

A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial

Peer to Peer (P2P): Mental Health Interventions With Persons With Substance Use Disorders

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity